BIORIMA
PROJECT DURATION:
01/2018
—
12/2022
TOTAL PROJECT DURATION:
4 Jahre
The Project
What are the risks of nanobiomaterials?
Nanobiomaterials are materials for biomedical applications in which at least one component is in the nanoscale range. In the EU project BIORIMA, more than 40 institutions from all over the world have joined forces to investigate and minimise the risks associated with nanobiomaterials. Methods for the identification, assessment, and management of risks associated with nanobiomaterials were developed for this purpose.
Our Role in the Project
Together with our project partners from Karolinska Institutet, the Consiglio Nazionale delle Ricerche and the Università Ca' Foscari Venezia, we tested whether silver and titanium nanoparticles can penetrate the skin and whether they trigger an immune response in the skin. Titanium nanoparticles are usually found in sun creams, silver nanoparticles in the coating of wound dressings.
To answer these questions HEALTH used Open Flow Microperfusion (OFM). OFM probes were implanted in the skin and interstitial fluid was collected. This allowed time-resolved monitoring of nanoparticles in the skin after they were applied to the skin surface. A new OFM experimental setup was used to investigate the non-specific immune response in the skin: The OFM probe was used to introduce the nanoparticles directly into the skin. At the same time, the interstitial fluid was removed with the same OFM probe and then analysed for non-specific immune responses.
Project Aim
BIORIMA has developed an integrated risk management (IRM) framework for nano-biomaterials (NBM) to be used in Advanced Therapeutic Medicinal Products (ATMP) and Medical Devices (MD).
Research groups
Downloads
Customer/Funding Organization
EUROPEAN COMMISSION
DIRECTORATE-GENERAL RESEARCH & INNOVATION
Project Partner
39 Partners
